Latest Automation News

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Aquirian Limited reports a 16.7% revenue increase alongside key operational advances at its Wubin facility and new leadership appointments, signaling strong momentum in mining services and technology.

RocketDNA Ltd has landed a $450,000 contract with BHP Mitsubishi Alliance to operate three SurveyBot drone units over nine months, reinforcing its foothold in the mining sector.

Vection Technologies has agreed to acquire Australian digital transformation firm DXLabs, adding immediate revenue and expanding its footprint across APAC with promising cross-sell opportunities.

Vection Technologies has secured $21 million through an upsized placement driven by strong defence sector momentum and announced a binding offer to acquire digital transformation firm DXLabs, bolstering its revenue and growth prospects.

FBR Limited has successfully placed the shortfall from its recent Share Purchase Plan, raising an additional $288,910 through issuing over 64 million shares. This capital injection supports the company’s ongoing development of its innovative robotic technologies.

FirstWave Cloud Technology is securing $2.5 million to accelerate growth through AI-driven compliance tools and the rollout of its NMIS Cloud service with Telmex, leveraging a vast existing user base and new global partnerships.

INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

Recce Pharmaceuticals has initiated patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, targeting a significant market with high diabetes prevalence. Interim results expected in early 2026 could accelerate regulatory approval and commercial launch.

Zimi Limited has completed its manufacturing transition, fulfilling over $1 million in backorders and restoring product availability in the Australian smart home market.